Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.

Date publication

septembre 2020

Journal

Gynecologic oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr KALBACHER Elsa

Tous les auteurs :
Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Barceló IB, Berton-Rigaud D, Ledermann JA, Rimel BJ, Herrstedt J, Lau S, du Bois A, Herráez AC, Kalbacher E, Buscema J, Lorusso D, Vergote I, Levy T, Wang P, de Jong FA, Gupta D, Matulonis UA

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32981695

Résumé

Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved for use in heavily pretreated patients and as maintenance treatment in patients with newly-diagnosed or recurrent ovarian cancer following a response to platinum-based chemotherapy. We present long-term safety data for niraparib from the ENGOT-OV16/NOVA trial.

Mots clés

Gynecologic oncology, Long-term safety, Niraparib, Ovarian cancer, Poly(ADP ribose) polymerase inhibitor

Référence

Gynecol. Oncol.. 2020 Sep 24;: